GlassScriptPhysician profile
Rachel E Strosnider
NPI 1770115149
$1,729.41
in general payments reported to CMS, 2019-2025
19 companies · $1,618 in 2025
The $1,618 reported for 2025 was more than what 89% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $12.04 · 2023: $47.23 · 2024: $51.74 · 2025: $1,618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,701 · Education: $16.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.81 |
| Education | $16.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $341.94 | 2025 | Caplyta |
| Abbvie INC. | $336.60 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $235.33 | 2025 | Rexulti |
| Vanda Pharmaceuticals INC. | $167.63 | 2025 | Fanapt, Hetlioz |
| Takeda Pharmaceuticals U.S.A., INC. | $102.47 | 2025 | Trintellix |
| Corium, LLC | $93.82 | 2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $80.79 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $47.84 | 2022-2025 | Spravato |
| Lundbeck LLC | $45.34 | 2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $45.17 | 2025 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $41.45 | 2025 | Rejoyn, Rexulti |
| Teva Pharmaceuticals USA, INC. | $34.23 | 2025 | Austedo Xr |
| Sage Therapeutics, LLC | $29.68 | 2025 | Zurzuvae |
| Alkermes, INC. | $28.15 | 2025 | Aristada, Lybalvi |
| Organon LLC | $27.74 | 2023 | Nexplanon |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $19.50 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.49 | 2023 | |
| Merck Sharp & Dohme LLC | $17.10 | 2024 | Gardasil 9, Vaxneuvance, Vaxelis |
| Astellas Pharma US INC | $15.14 | 2024 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rachel Strosnider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.